MapLight Therapeutics
MPLT
81 hedge funds and large institutions have $502M invested in MapLight Therapeutics in 2026 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 26 increasing their positions, 13 reducing their positions, and 14 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 13
57% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 14
24% more capital invested
Capital invested by funds: $405M → $502M (+$97M)
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
9% more funds holding
Funds holding: 74 → 81 (+7)
7.37% more ownership
Funds ownership: 50.84% → 58.21% (+7.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
+$12.1M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$6.71M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$4.44M |
| 4 |
BlackRock
New York
|
+$4.37M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$9.66M |
| 2 |
JG
Jain Global
New York
|
-$5.76M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.34M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.17M |
| 5 |
Lazard Asset Management
New York
|
-$1.17M |
MPLT Hedge Fund Activity: Q1 2026 in Review
81 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in MapLight Therapeutics (MPLT) for Q1 2026, worth a combined $502M — up 24% from $405M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new MPLT positions and 14 closed out — a net gain of 8 holders — while 26 added to existing stakes and 13 trimmed.
The largest buyer was Blue Owl Capital Holdings, adding an estimated $12.1M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $9.66M sold.
- 81 institutional investors held MapLight Therapeutics (MPLT) as of Q1 2026, up from 74 in Q4 2025.
- Funds reported $502M of MapLight Therapeutics stock for Q1 2026, up 24% quarter-over-quarter.
- 22 funds opened new MapLight Therapeutics positions in Q1 2026 and 14 closed out, a net change of +8 holders.
- The largest MapLight Therapeutics buyer in Q1 2026 was Blue Owl Capital Holdings, an estimated $12.1M added.
- The largest MapLight Therapeutics seller in Q1 2026 was Perceptive Advisors, an estimated $9.66M sold.
Based on aggregated 13F filings for Q1 2026.